Stephen E. Spurgeon
Oregon Health & Science University(US)
Publications by Year
Research Areas
Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Chronic Myeloid Leukemia Treatments, Viral-associated cancers and disorders, CAR-T cell therapy research
Most-Cited Works
- → Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma(2013)1,669 cited
- → Functional genomic landscape of acute myeloid leukaemia(2018)1,424 cited
- → Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia(2014)584 cited
- → Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results(2015)398 cited
- → Integrative analysis of drug response and clinical outcome in acute myeloid leukemia(2022)346 cited
- → Postibrutinib outcomes in patients with mantle cell lymphoma(2016)276 cited
- → A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)(2014)248 cited
- → Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma(2014)207 cited
- → Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma(2022)199 cited
- → Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening(2012)149 cited